Genentech’s Potential $5 Billion Blockbuster Drug

Home/Financial/Genentech’s Potential $5 Billion Blockbuster Drug

Genentech’s Potential $5 Billion Blockbuster Drug

Ron Leuty of the SF Business Times has a feature about Genentech’s Ocrelizumab, which has blockbuster potential.

The intro:

“Genentech Inc. could seek regulatory approval early next year for an experimental drug that in a late-stage trial showed that it could slow progression of a tough-to-treat form of multiple sclerosis, at least in the short term. The drug, a humanized monoclonal antibody called ocrelizumab, would be a huge win for the South San Francisco-based biotech powerhouse, as well as its parent company Roche (SWX: RO), and MS patients.”
Full article

More coverage:

Reuters: Roche drug succeeds in hard-to-treat form of multiple sclerosis

MS Today: Could Genentech’s Ocrelizumab Become the First Effective Primary Progressive MS Therapy?

September 29th, 2015|